Pathstone Family Office’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | $38.7M | Buy |
374,273
+149,093
| +66% | +$16.1M | 0.29% | 55 |
|
|
2023
Q2 | $26.6M | Buy |
225,180
+2,158
| +1% | +$245K | 0.38% | 56 |
|
|
2023
Q1 | $23.4M | Sell |
223,022
-296,058
| -57% | -$32M | 0.38% | 51 |
|
|
2022
Q4 | $62.4M | Buy |
519,080
+57,480
| +12% | +$5.88M | 0.53% | 43 |
|
|
2022
Q3 | $40M | Buy |
461,600
+266,645
| +137% | +$23.8M | 0.36% | 48 |
|
|
2022
Q2 | $17.8M | Buy |
194,955
+12,371
| +7% | +$1.1M | 0.39% | 49 |
|
|
2022
Q1 | $15.1M | Buy |
182,584
+4,486
| +3% | +$354K | 0.35% | 39 |
|
|
2021
Q4 | $13.7M | Buy |
178,098
+9,152
| +5% | +$729K | 0.34% | 42 |
|
|
2021
Q3 | $12.7M | Buy |
168,946
+28,747
| +21% | +$2.19M | 0.37% | 36 |
|
|
2021
Q2 | $10.9M | Buy |
140,199
+540
| +0.4% | +$40.2K | 0.33% | 45 |
|
|
2021
Q1 | $10.3M | Buy |
139,659
+34,154
| +32% | +$2.52M | 0.35% | 44 |
|
|
2020
Q4 | $8.23M | Buy |
105,505
+10,361
| +11% | +$792K | 0.34% | 47 |
|
|
2020
Q3 | $7.53M | Sell |
95,144
-1,995
| -2% | -$156K | 0.82% | 26 |
|
|
2020
Q2 | $7.17M | Buy |
97,139
+43,493
| +81% | +$3.27M | 0.85% | 27 |
|
|
2020
Q1 | $3.94M | Buy |
53,646
+31,311
| +140% | +$2.46M | 0.56% | 38 |
|
|
2019
Q4 | $19.4M | Sell |
22,335
-438
| -2% | -$36K | 0.21% | 49 |
|
|
2019
Q3 | $1.83M | Sell |
22,773
-798
| -3% | -$64K | 0.24% | 48 |
|
|
2019
Q2 | $1.89M | Sell |
23,571
-50,817
| -68% | -$3.89M | 0.22% | 51 |
|
|
2019
Q1 | $5.91M | Buy |
74,388
+2,852
| +4% | +$213K | 0.75% | 23 |
|
|
2018
Q4 | $5.21M | Buy |
71,536
+1,092
| +2% | +$77.1K | 1.5% | 9 |
|
|
2018
Q3 | $4.77M | Buy |
70,444
+112
| +0.2% | +$7.13K | 1.49% | 7 |
|
|
2018
Q2 | $4.07M | Sell |
70,332
-6,148
| -8% | -$347K | 3% | 4 |
|
|
2018
Q1 | $3.98M | Buy |
76,480
+1
| +0% | +$54 | 2.22% | 7 |
|
|
2017
Q4 | $35.3M | Sell |
76,479
-1,744
| -2% | -$96.7K | 19.55% | 2 |
|
|
2017
Q3 | $4.78M | Sell |
78,223
-19
| -0% | -$1.15K | 4.31% | 3 |
|
|
2017
Q2 | $4.78M | Sell |
78,242
-1,789
| -2% | -$109K | 2.02% | 7 |
|
|
2017
Q1 | $4.85M | Sell |
80,031
-1,362
| -2% | -$82.6K | 2.67% | 5 |
|
|
2016
Q4 | $4.57M | Sell |
81,393
-14,524
| -15% | -$850K | 2.91% | 6 |
|
|
2016
Q3 | $5.71M | Sell |
95,917
-17,022
| -15% | -$995K | 5.88% | 3 |
|
|
2016
Q2 | $6.21M | Buy |
112,939
+97,984
| +655% | +$5.21M | 5.9% | 4 |
|
|
2016
Q1 | $755K | Buy |
+14,955
| New | +$732K | 1.53% | 9 |
|
|
2015
Q4 | – | Sell |
-126
| Closed | -$6K | – | 139 |
|
|
2015
Q3 | $6K | Buy |
+126
| New | +$6.69K | 0.02% | 115 |
|
|
2014
Q4 | – | Sell |
-818
| Closed | -$46K | – | 197 |
|
|
2014
Q3 | $46K | Sell |
818
-1,278
| -61% | -$71.8K | 0.14% | 55 |
|
|
2014
Q2 | $116K | Hold |
2,096
| – | – | 0.33% | 13 |
|
|
2014
Q1 | $114K | Sell |
2,096
-21
| -1% | -$1.09K | 0.3% | 13 |
|
|
2013
Q4 | $101K | Buy |
2,117
+1,725
| +440% | +$78.9K | 0.22% | 21 |
|
|
2013
Q3 | $17K | Sell |
392
-2,081
| -84% | -$95K | 0.07% | 141 |
|
|
2013
Q2 | $110K | Buy |
+2,473
| New | +$110K | 0.13% | 46 |
|
Other funds holding MRK
Pathstone Family Office's MRK Position: Q3 2023 in Review
Pathstone Family Office increased its Merck (MRK) stake by 66% in Q3 2023, buying an estimated $16.1M and bringing the position to 374,273 shares worth $38.7M. The position accounts for 0.29% of the portfolio, ranked #55.
Pathstone Family Office first reported a position in MRK in Q2 2013 and has held it in 38 quarters since. The position peaked at $62.4M in Q4 2022. 3,213 funds tracked by Wall St. Rank hold MRK as of Q3 2023.
- Pathstone Family Office held 374,273 shares of Merck worth $38.7M as of Q3 2023.
- Pathstone Family Office bought 149,093 Merck shares in Q3 2023, an estimated $16.1M.
- Merck made up 0.29% of Pathstone Family Office's portfolio in Q3 2023, its #55 holding.
- Pathstone Family Office first reported a position in Merck in Q2 2013 and has held it in 38 quarters since.
- Pathstone Family Office's Merck position peaked at $62.4M in Q4 2022.
- 3,213 funds tracked by Wall St. Rank held Merck as of Q3 2023.
Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.